India should take a cue from the biotech hotbeds of the U.S. and U.K., a local trade groups says, investing in infrastructure to help foster startups and grow innovation clusters of its own.
A powdered measles vaccine could mean a cheaper option for the developing world that eliminates storage, contamination and waste challenges. And researchers now have one that looks safe in Phase I.
Selling off OTC businesses is the trend du jour in Big Pharma, but Merck KGaA is not jumping on the bandwagon. The company is planning to hold on to its consumer healthcare unit in a move that could deliver a much-needed boost to its slumping drug portfolio.
Some good news for emerging-market ambitions: China is backpedaling on price caps. After shortages prompted the government to ease up on certain price controls earlier this year, officials are now preparing to lift the price controls as early as Jan. 1.
Actavis has a lot to do as it works to bring new acquisition Allergan into the fold. And finding ways to grow the California company's products in China is high on the list.
The FDA is extending its tentacles deeper into China, which exported medical devices worth $3.5 billion to the U.S. in 2012, according to the U.S. Department of Commerce.
Minnesota-based device giant St. Jude Medical is beating the bushes in Malaysia, possibly looking to expand its production and services operations there, Malaysia's New Straits Times reported.
Neopharma, based in the United Arab Emirates, will build a plant in a new industrial city being developed in the south of the country. B.R. Shetty, who controls both Neopharma and New Medical Center Group of Companies, has pledged to spend 1 billion Saudi riyals ($266.5 million) to build both a drug manufacturing facility and a hospital in Jarzan City.
When Merck's Indian JV, Hilleman Laboratories, teamed up in June with Swedish biotech Gotovax AB, the plan was to get an affordable cholera vaccine to the developing world. Just a few months out, it's inked a pact to make that happen faster.
Bribery and pricing investigations aren't scaring Johnson & Johnson away from China. CEO Alex Gorsky tells The Wall Street Journal that his company is expanding full speed ahead in the fast-growing emerging market--and is actively looking at deals there to boost pharma sales.